Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular DystrophyGlobeNewsWire • 12/15/23
Wave Life Sciences stock slides 31% after company prices $100 million secondary share offeringMarket Watch • 12/07/23
Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin DeficiencyGlobeNewsWire • 12/06/23
Wave Life Sciences to Present at 6ᵗʰ Annual Evercore ISI HealthCONx ConferenceGlobeNewsWire • 11/22/23
Wave Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 11/09/23
Wave Life Sciences Third Quarter 2023 Financial Results Scheduled for November 9, 2023GlobeNewsWire • 11/03/23
Wave Life Sciences (WVE) Soars 8.7%: Is Further Upside Left in the Stock?Zacks Investment Research • 09/29/23
Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D DayGlobeNewsWire • 09/28/23
Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines ConferenceGlobeNewsWire • 09/25/23
Wave Life Sciences to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/06/23
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”GlobeNewsWire • 09/05/23
Wave Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 08/03/23
Wave Life Sciences Second Quarter 2023 Financial Results Scheduled for August 3, 2023GlobeNewsWire • 07/27/23
Wave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated Amyotrophic Lateral Sclerosis and Frontotemporal DementiaGlobeNewsWire • 05/23/23
Wave Life Sciences to Highlight Leading RNA Editing Capability and Multimodal Discovery and Development Platform at ASGCT 26th Annual MeetingGlobeNewsWire • 05/16/23